Insmed reported $-200.28M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
DBV Technologies USD -47.9M 2.85M Mar/2026
Gilead Sciences USD 2.68B 284M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -200.28M 49.43M Mar/2026
Novartis USD 4.18B 118M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
Vertex Pharmaceuticals USD 1.14B 124.5M Mar/2026